Haemonetics Quarterly Income Statement
NYSE: HAEHealthcareMedical DevicesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Haemonetics revenue and earnings
In the quarter ended Jun 27, 2026, Haemonetics generated $339.4 million in revenue, up 5.6% from the same quarter a year earlier. Net income was $33.0 million (-3.0% year over year), for a net margin of 9.7% versus a median of 11.8% in the prior 5 quarters. Gross margin was 59.8% (down from 59.8%) and operating margin 16.9%.
Diluted earnings per share came in at $0.72, up from $0.70.
Summary generated from market data by MetaCap's automated system. Methodology
Haemonetics income statement (quarterly)
| Quarter (USD) | Q1 20272026-06-27 | Q4 20262026-03-28 | Q3 20262025-12-27 | Q2 20262025-09-27 | Q1 20262025-06-28 | Q4 20252025-03-29 | Q3 20252024-12-28 | Q2 20252024-09-28 | Q1 20252024-06-29 | Q4 20242024-03-30 | Q3 20242023-12-30 | Q2 20242023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 339.38M | 346.35M | 338.97M | 327.31M | 321.39M | 330.60M | 348.54M | 345.51M | 336.17M | 343.29M | 336.25M | 318.18M |
| Revenue growth (YoY) | +5.60% | +4.76% | -2.75% | -5.27% | -4.40% | -3.70% | +3.66% | +8.59% | +7.98% | +12.77% | +10.14% | +6.96% |
| Cost of Revenue | 136.58M | 148.14M | 136.58M | 132.57M | 129.15M | 137.55M | 155.00M | 158.07M | 161.25M | 167.38M | 158.38M | 147.67M |
| Gross Profit | 202.80M | 198.21M | 202.39M | 194.74M | 192.24M | 193.05M | 193.55M | 187.44M | 174.92M | 175.91M | 177.87M | 170.51M |
| Operating Expenses | 145.34M | 221.24M | 134.99M | 136.25M | 138.37M | 121.72M | 134.52M | 135.74M | 135.17M | 145.96M | 131.89M | 135.21M |
| Research & Development | 16.20M | 14.45M | 14.19M | 14.87M | 16.26M | 18.30M | 15.83M | 14.14M | 14.45M | 15.86M | 13.27M | 12.66M |
| Selling, General & Admin | 118.94M | 120.93M | 109.15M | 101.61M | 110.72M | 115.14M | 106.46M | 106.95M | 108.25M | 109.26M | 111.71M | 115.32M |
| Operating Income | 57.46M | -23.02M | 67.40M | 58.49M | 53.87M | 71.33M | 59.03M | 51.70M | 39.76M | 29.94M | 45.98M | 35.30M |
| Other Income (Expense) | -9.88M | -5.37M | -7.42M | -7.21M | -8.70M | -598.00K | -9.11M | -6.99M | 6.96M | -6.53M | -1.95M | -2.47M |
| Pretax Income | 47.57M | -28.40M | 59.98M | 51.28M | 45.17M | 70.74M | 49.92M | 44.70M | 46.71M | 23.41M | 44.03M | 32.83M |
| Income Tax | 14.56M | -8.25M | 15.23M | 12.60M | 11.14M | 12.76M | 12.42M | 10.87M | 8.34M | 3.05M | 12.79M | 7.92M |
| Net Income | 33.01M | -20.15M | 44.74M | 38.68M | 34.03M | 57.98M | 37.49M | 33.83M | 38.37M | 20.37M | 31.24M | 24.91M |
| Net Income growth (YoY) | -3.00% | -134.75% | +19.33% | +14.34% | -11.32% | +184.68% | +20.02% | +35.82% | -6.50% | -30.68% | -5.17% | -24.97% |
| EPS (Basic) | 0.73 | -0.42 | 0.96 | 0.81 | 0.71 | 1.17 | 0.75 | 0.66 | 0.75 | 0.40 | 0.62 | 0.49 |
| EPS (Diluted) | 0.72 | -0.41 | 0.95 | 0.81 | 0.70 | 1.17 | 0.74 | 0.66 | 0.74 | 0.40 | 0.61 | 0.48 |
| Shares Outstanding (Basic) | 45.36M | — | 46.79M | 47.59M | 48.11M | — | 50.29M | 50.90M | 50.94M | — | 50.77M | 50.73M |
| Shares Outstanding (Diluted) | 45.70M | — | 46.99M | 47.66M | 48.35M | — | 50.64M | 51.24M | 51.56M | — | 51.45M | 51.40M |
| EBITDA | 84.57M | 4.29M | 94.78M | 86.75M | 82.63M | 99.54M | 88.05M | 80.91M | 68.89M | 57.58M | 69.51M | 58.32M |
| Gross Margin | 59.76% | 57.23% | 59.71% | 59.50% | 59.82% | 58.39% | 55.53% | 54.25% | 52.03% | 51.24% | 52.90% | 53.59% |
| Operating Margin | 16.93% | -6.65% | 19.88% | 17.87% | 16.76% | 21.58% | 16.94% | 14.96% | 11.83% | 8.72% | 13.67% | 11.10% |
| Net Margin | 9.73% | -5.82% | 13.20% | 11.82% | 10.59% | 17.54% | 10.76% | 9.79% | 11.41% | 5.93% | 9.29% | 7.83% |
This table shows 12 quarterly periods of Haemonetics's income statement, from Q1 2027 back to Q2 2024, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow HAE's reporting calendar. What is a income statement?